ProfileGDS4814 / ILMN_1909230
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 1% 17% 22% 5% 27% 46% 42% 2% 1% 5% 2% 2% 37% 40% 25% 4% 2% 4% 37% 7% 32% 31% 23% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)36.06571
GSM780708Untreated after 4 days (C2_1)42.834817
GSM780709Untreated after 4 days (C3_1)44.054722
GSM780719Untreated after 4 days (C1_2)39.45175
GSM780720Untreated after 4 days (C2_2)45.049227
GSM780721Untreated after 4 days (C3_2)49.144346
GSM780710Trastuzumab treated after 4 days (T1_1)48.301142
GSM780711Trastuzumab treated after 4 days (T2_1)37.92
GSM780712Trastuzumab treated after 4 days (T3_1)36.26741
GSM780722Trastuzumab treated after 4 days (T1_2)39.44175
GSM780723Trastuzumab treated after 4 days (T2_2)37.39562
GSM780724Trastuzumab treated after 4 days (T3_2)37.90092
GSM780713Pertuzumab treated after 4 days (P1_1)47.110737
GSM780714Pertuzumab treated after 4 days (P2_1)47.633440
GSM780715Pertuzumab treated after 4 days (P3_1)44.652525
GSM780725Pertuzumab treated after 4 days (P1_2)38.98874
GSM780726Pertuzumab treated after 4 days (P2_2)37.48822
GSM780727Pertuzumab treated after 4 days (P3_2)38.68794
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)47.096837
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.06257
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)45.991432
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)45.755331
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)44.215623